Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750188 · ClinicalTrials.gov registry record
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
A clinical trial, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 125
- Enrollment target
NCT03750188: Completed study, sponsored by Bracco Diagnostics.
NCT03750188 is a clinical trial that has completed, run by Bracco Diagnostics. The registered enrollment target is 125 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03750188 has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 125 participants
- Enrollment target
Study Summary
Safety and Efficacy Study in pediatric subjects \<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.
Primary Outcome
Blinded reader will assess the border delineation of lesion based on a 5 point scale, none (0) - Excellent (4)
Interventions
- DRUG ProHance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2019-10-16 |
What the finished NCT03750188 record still lists
NCT03750188 is an observational study that tracks outcomes without assigning an intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ProHance is the first listed.
NCT03750188 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03750188 about?
NCT03750188 is a clinical study titled "Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs". Safety and Efficacy Study in pediatric subjects \<2 years of age who have undergone Brain or Spine MRI pre and post 0.1 mmol/kg ProHance administration. Imaging conditions will represent those in routine clinical practice. Retrospective enrolment with a prospective blinded read.
What is the current status of trial NCT03750188?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2018-11-01. Estimated completion is 2019-10-16.
What interventions are being tested in trial NCT03750188?
The interventions under investigation include: ProHance (DRUG).
Who is sponsoring clinical trial NCT03750188?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI